BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Gong SS, Fan YH, Han QQ, Lv B, Xu Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol 2019; 25(18): 2240-2250 [PMID: 31143074 DOI: 10.3748/wjg.v25.i18.2240]
URL: https://www.wjgnet.com/1007-9327/full/v25/i18/2240.htm
Number Citing Articles
1
Ferdinando D’Amico, Stéphane Nancey, Silvio Danese, Laurent Peyrin-Biroulet. A Practical Guide for Faecal Calprotectin Measurement: Myths and RealitiesJournal of Crohn's and Colitis 2021; 15(1): 152 doi: 10.1093/ecco-jcc/jjaa093
2
Zi-Ning Zhang, Li-Xuan Sang. Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of itWorld Journal of Gastroenterology 2024; 30(36): 4025-4030 doi: 10.3748/wjg.v30.i36.4025
3
Shailesh Perdalkar, Pooja Basthi Mohan, Balaji Musunuri, Siddheesh Rajpurohit, Shiran Shetty, Krishnamurthy Bhat, Cannanore Ganesh Pai. Thiopurine therapy in inflammatory bowel disease in the pandemic era: Safe or unsafe?International Immunopharmacology 2023; 116: 109597 doi: 10.1016/j.intimp.2022.109597
4
Scott D. Lee, Jessica R. Allegretti, Flavio Steinwurz, Susan B. Connelly, Nervin Lawendy, Jerome Paulissen, Krisztina B. Gecse. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscoreBMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-022-02508-2
5
Antonio Pizuorno Machado, Abdullah Salim Shaikh, Alice Saji, Malek Shatila, Isabella Glitza Oliva, Yinghong Wang, Anusha Shirwaikar Thomas. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with CancerCancers 2024; 16(10): 1919 doi: 10.3390/cancers16101919
6
Vincenzo Craviotto, Federica Furfaro, Laura Loy, Alessandra Zilli, Laurent Peyrin-Biroulet, Gionata Fiorino, Silvio Danese, Mariangela Allocca. Viral infections in inflammatory bowel disease: Tips and tricks for correct managementWorld Journal of Gastroenterology 2021; 27(27): 4276-4297 doi: 10.3748/wjg.v27.i27.4276
7
Alyssa K. Mezochow, Douglas E. Schaubel, Eliot G. Peyster, James D. Lewis, David S. Goldberg, Therese Bittermann. Hospitalizations for opportunistic infections following transplantation and associated risk factors: A national cohort study of Medicare beneficiariesTransplant Infectious Disease 2024; 26(4) doi: 10.1111/tid.14317
8
S. A. Tsvetikova, E. E. Kruglov, L. G. Danilov, D. S. Zilov, Yu. V. Myakisheva, M. A. Makarova, L. A. Kaftyreva, E. I. Koshel. Composition and Pathogenic Potential of Mucosal Microbiota in Ulcerative ColitisRussian Journal of Bioorganic Chemistry 2024; 50(2): 582 doi: 10.1134/S1068162024110463
9
Anand Kumar, Tatiana Teslova, Erin Taub, Joshua D. Miller, Dana J. Lukin. Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious ComplicationsDigestive Diseases and Sciences 2021; 66(6): 2005 doi: 10.1007/s10620-020-06439-4
10
Cátia Arieira, Francisca Dias de Castro, Tiago Cúrdia Gonçalves, Maria J. Moreira, José Cotter. Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?Scandinavian Journal of Gastroenterology 2020; 55(8): 920 doi: 10.1080/00365521.2020.1792543
11
Maede Ghanaeipour, Nima Behnaminia, Erfan Khadem, Amirhossein Nafari. The Risk of Opportunistic Infections in Patients with Inflammatory Bowel DiseaseThe International Journal of Gastroenterology and Hepatology Diseases 2022; 1(1) doi: 10.2174/2666290601666220124111511
12
Sheng-Bo Fang, Yan-Qing Song, Chun-Yan Zhang, Li-Bo Wang. Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysisWorld Journal of Pediatrics 2022; 18(1): 27 doi: 10.1007/s12519-021-00486-1
13
Kathryn Gazelakis, Isabel Chu, Catherine Martin, Miles P. Sparrow. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levelsInternal Medicine Journal 2024; 54(1): 139 doi: 10.1111/imj.16105
14
Jennie Clough, Michael Colwill, Andrew Poullis, Richard Pollok, Kamal Patel, Sailish Honap. Biomarkers in inflammatory bowel disease: a practical guideTherapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848241251600
15
Koji Yokoyama, Masahiko Sakabe, Mitsukazu Mamada. A Case of Refractory Kawasaki Disease With Yersinia pseudotuberculosis Infection Successfully Treated With Cefotaxime Following Immunosuppressive TherapyCureus 2024;  doi: 10.7759/cureus.73866
16
Trusha Patel, Andrew B. Grossman. Updates in Healthcare Maintenance and Monitoring of Children with Inflammatory Bowel Disease in the Era of Biologic TherapiesCurrent Treatment Options in Pediatrics 2019; 5(4): 466 doi: 10.1007/s40746-019-00181-4
17
Luigi Marongiu, Sascha Venturelli, Heike Allgayer. Involvement of HHV-4 (Epstein–Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-AnalysisCancers 2022; 14(20): 5085 doi: 10.3390/cancers14205085